COMMUNIQUÉS West-GlobeNewswire

Teva Announces Launch of Offering of Senior Notes
07/09/2026
TEL AVIV, Israel, Sept. 07, 2026 (GLOBE NEWSWIRE) -- Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) (“ Teva ”) announced today its intention to issue senior notes through its special purpose finance [...]
Virbac : Déclaration d'actions et de droits de vote 07/2026
07/09/2026
DÉCLARATION D’ACTIONS ET DE DROITS DE VOTE Informations relatives au nombre total de droits de vote et au nombre d’actions composant le capital (Article 223-16 du Règlement Général de l’Autorité des Marchés Financiers) [...]
Virbac : Declaration of the number of shares and voting rights 07/2026
07/09/2026
DECLARATION OF THE NUMBER OF SHARES AND VOTING RIGHTS Information on the total number of voting rights and of shares representing the share capital (Article 223-16 of the General regulations of the French Financial [...]
Virbac : Déclaration d'actions et de droits de vote 08/2026
07/09/2026
DÉCLARATION D’ACTIONS ET DE DROITS DE VOTE Informations relatives au nombre total de droits de vote et au nombre d’actions composant le capital (Article 223-16 du Règlement Général de l’Autorité des Marchés Financiers) [...]
Virbac : Declaration of the number of shares and voting rights 08/2026
07/09/2026
DECLARATION OF THE NUMBER OF SHARES AND VOTING RIGHTS Information on the total number of voting rights and of shares representing the share capital (Article 223-16 of the General regulations of the French Financial [...]
Rezubio Announces FDA and NMPA IND Clearances and First Cohort Dosing of RZ-520, a Novel Inhaled Therapy for Chronic Respiratory Diseases
07/09/2026
ZHUHAI, China, Sept. 06, 2026 (GLOBE NEWSWIRE) -- Rezubio today announced that it has successfully completed dosing of the first cohort in its Phase 1 clinical trial following clearances from the US FDA and Chinese NMPA [...]
Pulmovant to Present Topline Results from the Phase 2 PHocus Study of Mosliciguat in Patients with Pulmonary Hypertension Associated with Interstitial Lung Disease (PH-ILD) at the ERS Congress 2026 on Tuesday, September 8, 2026
06/09/2026
WALTHAM, Mass., Sept. 06, 2026 (GLOBE NEWSWIRE) -- Pulmovant, a clinical-stage biotechnology company committed to transforming the lives of patients with pulmonary diseases, and a Roivant (Nasdaq: ROIV) company, today [...]
Roivant to Present Topline Results from the Phase 2 PHocus Study of Mosliciguat in Patients with Pulmonary Hypertension Associated with Interstitial Lung Disease (PH-ILD) at the ERS Congress 2026 on Tuesday, September 8, 2026, and Host Investor Call
06/09/2026
BASEL, Switzerland and LONDON and NEW YORK, Sept. 06, 2026 (GLOBE NEWSWIRE) -- Roivant (Nasdaq: ROIV) and Pulmovant today announced that results from the Phase 2 PHocus study of mosliciguat in patients with pulmonary [...]
Conavi Medical Announces Media and Digital Marketing Agreements
05/09/2026
TORONTO, Sept. 04, 2026 (GLOBE NEWSWIRE) -- Conavi Medical Corp. (TSXV: CNVI) (OTCQB: CNVIF) (“Conavi” or the “Company”), a commercial-stage medical device company focused on designing, manufacturing, and marketing [...]
Schedule update: Stryker to participate in the 2026 Wells Fargo Healthcare Conference
05/09/2026
Portage, Michigan, Sept. 04, 2026 (GLOBE NEWSWIRE) -- Stryker (NYSE:SYK) will participate in the 2026 Wells Fargo Healthcare Conference on Tuesday, September 8, 2026 , at the Encore Boston Harbor, as previously reported [...]
The International Myeloma Foundation Mourns the Passing of Former IMF Board Member Dr. Robert A. Kyle — The Father of Multiple Myeloma
05/09/2026
STUDIO CITY, Calif., Sept. 04, 2026 (GLOBE NEWSWIRE) -- It is with great sadness that the International Myeloma Foundation (IMF) shares news of the passing of Dr. Robert A. Kyle at age 98 — the Father of Myeloma and a [...]
Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
04/09/2026
WESTLAKE VILLAGE, Calif., Sept. 04, 2026 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), a commercial-stage biopharmaceutical company focused on developing meaningful innovations in immuno-dermatology [...]
Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
04/09/2026
NEW YORK, Sept. 04, 2026 (GLOBE NEWSWIRE) -- Syndax Pharmaceuticals (Nasdaq: SNDX), a commercial-stage biopharmaceutical company advancing innovative cancer therapies, today announced that on September 1, 2026, the [...]
Spyre Therapeutics Announces Grants of Inducement Awards
04/09/2026
WALTHAM, Mass., Sept. 04, 2026 (GLOBE NEWSWIRE) -- Spyre Therapeutics, Inc. (NASDAQ: SYRE) (the “Company” or “Spyre”), a clinical-stage biotechnology company committed to developing next-generation therapies that [...]
Apnimed, Inc. Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
04/09/2026
CAMBRIDGE, Mass., Sept. 04, 2026 (GLOBE NEWSWIRE) -- Apnimed, Inc. (Nasdaq: APMD) (“Apnimed” or the “Company”), a late stage clinical pharmaceutical company dedicated to the discovery, development and commercialization [...]
InspireMD Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
04/09/2026
MIAMI, Sept. 04, 2026 (GLOBE NEWSWIRE) -- InspireMD, Inc. (Nasdaq: NSPR) (“InspireMD” or the “Company”), developer of the CGuard™ Prime carotid stent system for the prevention of stroke, today announced that the [...]
Kiniksa Pharmaceuticals to Present at Wells Fargo 21st Annual Healthcare Conference
04/09/2026
LONDON, Sept. 04, 2026 (GLOBE NEWSWIRE) -- Kiniksa Pharmaceuticals International, plc (Nasdaq: KNSA) today announced that management will participate in a fireside chat at the Wells Fargo 21 st Annual Healthcare [...]
Vor Bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
04/09/2026
BOSTON, Sept. 04, 2026 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage biotechnology company transforming the treatment of autoimmune diseases, today announced that, on September 1, 2026, the Compensation [...]
Vera Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
04/09/2026
BRISBANE, Calif., Sept. 04, 2026 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (Nasdaq: VERA) today announced that, on September 1, 2026, the Compensation Committee of the Board of Directors (Compensation Committee) of [...]

Pages